NovoCure Limited

NASDAQ: NVCR · Real-Time Price · USD
11.78
0.19 (1.64%)
At close: Aug 15, 2025, 3:05 PM

NovoCure Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-168.63M -207.04M -92.53M -58.35M
Depreciation & Amortization
-14.41M 10.97M 10.62M 10.25M
Stock-Based Compensation
160.03M 115.61M 106.95M 94.9M
Other Working Capital
384K -5.8M -666K -6.46M
Other Non-Cash Items
932K -22.43M -6.05M 3.01M
Deferred Income Tax
n/a n/a n/a 3.88M
Change in Working Capital
-4.3M 29.56M 11.8M 29.07M
Operating Cash Flow
-26.37M -73.34M 30.79M 82.76M
Capital Expenditures
-42.85M -27.09M -21.36M -24.17M
Cash Acquisitions
n/a n/a 118.6M 120.66M
Purchase of Investments
-875.39M -1B -1.3B -1.08B
Sales Maturities Of Investments
778M 1.21B 1.18B 958M
Other Investing Acitivies
n/a n/a -118.6M -120.66M
Investing Cash Flow
-140.24M 184.15M -139.96M -144.83M
Debt Repayment
84.01M -10K -28K -26K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
2.16M 11.38M 10.29M 21.18M
Financial Cash Flow
90.31M 15.79M 15.49M 25.7M
Net Cash Flow
-76.47M 126.73M -93.78M -36.56M
Free Cash Flow
-69.22M -100.43M 9.43M 58.59M